Motus gi completes first clinical evaluation of new pure-vu® gastro in upper gastrointestinal (gi) procedures to support fda submission

- pure-vu gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - - on track to submit a 510(k) to the u.s. fda for the pure-vu gen 4 gastro device in q4 2023 to support the 400,000 upper gi bleeds and other procedures with impaired visualization in the u.s. - - pure-vu gen 4 gastro to be used during the 9 th ieced live endoscopy course 2023 through the pentax learning center in june 2023 - fort lauderdale, fla., may 17, 2023 (globe newswire) -- motus gi holdings, inc., (nasdaq: mots) (“motus gi” or the “company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced in collaboration with the ecuadorian institute of digestive diseases (ieced) initiation of a clinical evaluation of the pure-vu gen 4 gastro, which is designed for upper gastrointestinal (gi) bleeding procedures - an area of high unmet patient need.
MOTS Ratings Summary
MOTS Quant Ranking